„Dostawa produktów leczniczych, leków biologicznych i immunoglobulin.”
Poland · Warszawa · how to bid here →
Your path to submission
- Deadline: 18 September at 00:00 — 7 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL.
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- 221% of the bids received came from small and medium-sized enterprises (119 procedures with a bid mix). Sector: 300%.n = 119
- In this sector the buyer awards roughly every 1 months (159 awards, most recently September 2026) — the next award is due around October 2026 by that rhythm. The last award went to Zarys International Sp. z o.o..n = 159
- 17% of this buyer's awards went to companies that had already won here before (331 awards since 2015, spread over 122 companies). That is well below the sector norm (54%) — this buyer switches suppliers more often than others.n = 331 awards since 2015
- The median procedure drew 2 bids (291 procedures with a bid count); 49% ended with a single bidder. Sector: median 3 bids.n = 291
- 15% of awards went to companies from abroad (331 awards with a known winner country). Sector average: 5%.n = 331
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 10/09/2026.
Foreign bidders
In Poland · Medical equipment & pharma, 5,084 contracts went to foreign companies over the last 3 years (of 271,407 recorded awards) — mostly from Germany, France, Czechia.
Typical field: median 2 (from 146 awards).
What the buyer is looking for
Przedmiot zamówienia: „Dostawa produktów leczniczych, leków biologicznych i immunoglobulin.” Zamówienie zostało podzielona na 14 części: Część nr 1 - „Tofacitinib citrate” Część nr 2 - „Etanercept” Część nr 3 - „Secukinumab” Część nr 4 - „Nintedanibum” Część nr 5 - „Adalimumab” Część nr 6 - „Tocilizumabum I” Część nr 7 - „Tocilizumabum II” Część nr 8 - „Immunoglobulin normal human 5%” Część nr 9 - „Produkty lecznicze I” Część nr 10 - „Produkty lecznicze II” Część nr 11 – „Golimumab” Część nr 12 – „Guselkumabum” Część nr 13 – „Ixekizumab” Część nr 14 – „Immunoglobulin normal human 10%” 2. Szczegółowy opis przedmiotu zamówienia zawierają niniejsza SWZ oraz: 1) załącznik nr 1 – formularz oferty; 2) załącznik nr 2 – formularz asortymentowo-cenowy odpowiednio dla części 1 - 14; 3) załącznik nr 3 – projektowane postanowienia umowy.
Selection criteria — in the procurement documents
The buyer states in the notice that the selection criteria are in the procurement documents (link on the right), not in the EU form. The document analysis below extracts them from there — bid and evidence in POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL, POL.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Urtica Sp. z o.o. | 9 | 2024–2026 |
| Bialmed Sp. z o.o. | 8 | 2024–2026 |
| Asclepios S.A. | 6 | 2024–2026 |
| Asclepios SA | 6 | 2024–2025 |
| URTICA Sp.z o.o. | 5 | 2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.
How to bid
Guide: how to apply on e-Zamówienia (Polen) → Registration, signature, fees — from the operator's bidder manual.